{"id":15683,"date":"2019-08-02T09:59:39","date_gmt":"2019-08-02T07:59:39","guid":{"rendered":"https:\/\/www.satt.fr\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/"},"modified":"2019-11-06T09:38:37","modified_gmt":"2019-11-06T08:38:37","slug":"hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/","title":{"rendered":"HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong><a href=\"http:\/\/www.hephaistos-pharma.com\/\" target=\"_blank\" rel=\"noopener noreferrer\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2019\/06\/Logo-Hephaistos-Pharma_carr\u00e9.png\" alt=\"\" width=\"126\" height=\"116\" \/><\/a>A l\u2019interface de l\u2019immunologie et de l\u2019oncologie, la soci\u00e9t\u00e9 de biotechnologie <\/strong><a href=\"http:\/\/www.hephaistos-pharma.com\/\"><strong>HEPHAISTOS-Pharma<\/strong><\/a><strong> cr\u00e9\u00e9e en juillet 2018 allie les expertises du Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL\u00a0: INSERM\/CNRS\/UCBL\/CLB\/HCL\/ISPB) et de la soci\u00e9t\u00e9 parisienne LPS-Biosciences sp\u00e9cialis\u00e9e dans l\u2019infectiologie et les vaccins. La soci\u00e9t\u00e9, laur\u00e9ate du concours d\u2019innovation i-Lab 2019, b\u00e9n\u00e9ficie du programme de co-maturation de PULSALYS dont l\u2019objectif est, dans le cadre de l\u2019immunoth\u00e9rapie anticanc\u00e9reuse, de mettre en oeuvre des mol\u00e9cules d\u2019origine bact\u00e9rienne pour stimuler le syst\u00e8me immunitaire.<\/strong><\/p>\n<div style=\"width: 521px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2019\/06\/HEPHAISTOS-WIP2019-Ceremony.jpg\" alt=\"\" width=\"511\" height=\"340\" \/><p class=\"wp-caption-text\">Remise du prix Europ\u00e9en Woman Innovator 2019 \u00e0 Martine Caroff<\/p><\/div>\n<p style=\"text-align: justify;\">N\u00e9e de la rencontre entre le Pr Charles Dumontet,\u00a0Chef d&#8217;\u00e9quipe au CRCL et les responsables de la soci\u00e9t\u00e9 de biotechnologies <a href=\"http:\/\/www.lpsbiosciences.com\/\">LPS-Biosciences<\/a> (cr\u00e9\u00e9e en 2011), dont le <a href=\"https:\/\/www.facebook.com\/watch\/?v=358146368380918\">Dr Martine Caroff<\/a>, fondatrice et directrice scientifique de la soci\u00e9t\u00e9, la jeune biotech <a href=\"http:\/\/www.hephaistos-pharma.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">HEPHAISTOS-Pharma<\/a> a pour ambition de r\u00e9v\u00e9ler tout le potentiel des traitements en oncologie \u00e0 base d\u2019anticorps gr\u00e2ce \u00e0 ses candidats immuno-stimulateurs. <em>\u00ab\u00a0Nous cherchions l\u2019opportunit\u00e9 de d\u00e9montrer l\u2019effet positif de nos mol\u00e9cules immuno-stimulantes (LPS) dans le traitement du cancer, en m\u00eame temps que le Pr Charles Dumontet \u00e9tait en qu\u00eate d\u2019une soci\u00e9t\u00e9 sp\u00e9cialiste de ce type de mol\u00e9cules\u00a0\u00bb<\/em> raconte Fr\u00e9d\u00e9ric Caroff, Pr\u00e9sident de HEPHAISTOS-Pharma. La rencontre est donc arriv\u00e9e \u00e0 point nomm\u00e9, et rapidement s\u2019est impos\u00e9e la cr\u00e9ation d\u2019une entit\u00e9 d\u00e9di\u00e9e \u00e0 la validation pr\u00e9clinique et clinique, assortie d\u2019une collaboration et d\u2019un transfert de technologie du CRCL vers la startup op\u00e9r\u00e9 par PULSALYS.<\/p>\n<p style=\"text-align: justify;\">Dans le programme de co-maturation \u00e9tabli entre les partenaires, <a href=\"http:\/\/www.hephaistos-pharma.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">HEPHAISTOS-Pharma<\/a> teste ses mol\u00e9cules candidats en collaboration avec l\u2019\u00e9quipe du Pr Dumontet, afin de valider leur efficacit\u00e9 sur divers mod\u00e8les de tumeurs chez les petits mammif\u00e8res (souris et rat).<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\"><strong>Des boosters de l\u2019immunit\u00e9 et un enjeu immense pour la gu\u00e9rison des cancers <\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><em><img loading=\"lazy\" decoding=\"async\" class=\" alignleft\" src=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2019\/06\/HEPHAISTOS-Sch\u00e9ma-MoA.png\" width=\"302\" height=\"170\" \/>\u00ab\u00a0Les immunoth\u00e9rapies offrent des r\u00e9sultats fantastiques sur diff\u00e9rents types de cancers, et ont d\u00e9j\u00e0 permis de gu\u00e9rir des patients en phase terminale\u00a0\u00bb<\/em> rappelle F. Caroff. H\u00e9las les taux de gu\u00e9rison des th\u00e9rapies actuelles sont encore faibles\u00a0: 25% des patients r\u00e9pondent positivement au traitement et seulement 10% des patients en moyenne sont totalement gu\u00e9ris sans risque de rechute<em>. \u00ab\u00a0L\u2019enjeu pour HEPHAISTOS-Pharma est de combler ce gap et de d\u00e9velopper des immuno-stimulateurs permettant de rendre efficaces les anticorps utilis\u00e9s en immunoth\u00e9rapie afin de transformer le taux de succ\u00e8s de 10% \u00e0 50% \u2026et nous esp\u00e9rons \u00e0 80%\u00a0\u00bb<\/em> affiche F. Caroff.<\/p>\n<p style=\"text-align: justify;\">En combinant ses candidats immunostimulants avec les th\u00e9rapies classiques, <em>HEPHAISTOS<\/em>-Pharma ambitionne ainsi de r\u00e9volutionner la prise en charge des cancers et de d\u00e9bloquer les m\u00e9canismes qui emp\u00eachent aujourd\u2019hui les immunoth\u00e9rapies d\u2019agir pleinement<em>. \u00ab\u00a0L\u2019effet de stimulation par les LPS du syst\u00e8me immunitaire (en particulier des macrophages qui enclenchent le processus de d\u00e9fense de l\u2019organisme) qui attaque les tumeurs est d\u2019ores et d\u00e9j\u00e0 d\u00e9montr\u00e9 sur la souris et sur le rat\u00a0\u00bb<\/em> indique-t-il. <em>HEPHAISTOS-<\/em>Pharma travaille sur plusieurs mod\u00e8les de tumeurs\u00a0: les lymphomes, pour lesquels un taux de r\u00e9ponse de 70% est obtenu avec la combinaison, et les ost\u00e9osarcomes, sur lesquels aucun traitement ne fonctionne bien et pour lesquels l\u2019injection des mol\u00e9cules LPS seules permet d\u00e9j\u00e0 un taux de gu\u00e9rison de 50%.<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\"><strong>Un programme bien \u00e9tabli avec l\u2019objectif d\u2019aller en clinique<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\">\u00ab\u00a0<em>La cr\u00e9ation de la startup HEPHAISTOS-Pharma est un embl\u00e9matique de la rencontre entre la sph\u00e8re acad\u00e9mique (CRCL) et le monde socio-\u00e9conomique (LPS-Biosciences) que PULSALYS encourage et accompagne au quotidien\u00a0<\/em>\u00bb dixit Laure Vidalain, chef de ce projet \u00e0 PULSALYS. <em>\u00ab\u00a0Le brevet issu du CRCL fait l\u2019objet <\/em><em>du programme de co-maturation soutenu par PULSALYS\u00a0et un essai est actuellement en cours jusqu\u2019en septembre 2019\u00bb<\/em> rappelle Joseph Andr\u00e9, responsable d\u2019investissement chez PULSALYS, indiquant qu\u2019une \u00e9tape majeure concernera la phase pr\u00e9clinique r\u00e9glementaire.\u00a0 <em>\u00ab\u00a0<\/em><em>Notre objectif est de valider l\u2019ensemble des \u00e9tudes pr\u00e9cliniques d\u2019ici 2 ans et de r\u00e9aliser ensuite les premiers essais cliniques \u00e0 Lyon en collaboration avec le centre L\u00e9on B\u00e9rard et les Hospices Civils de Lyon\u00a0\u00bb<\/em><strong>\u00a0 <\/strong>annonce F. Caroff, pr\u00e9cisant le soutien de l\u2019Aderly pour l\u2019installation de la soci\u00e9t\u00e9 dans le quartier de Gerland et l\u2019embauche d\u2019une premi\u00e8re salari\u00e9e issue de l\u2019IMIS de Lyon. Pour ce faire l\u2019entreprise aura besoin de lever des fonds aupr\u00e8s d\u2019investisseurs priv\u00e9s fin 2019 et fin 2020.<\/p>\n<p><iframe loading=\"lazy\" title=\"Laur\u00e9ats i-Lab 2019 - T\u00e9moignage de Fr\u00e9d\u00e9ric Caroff pour la startup HEPHAISTOS PHARMA\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/ElmoWT3MlzI?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<table border=\"1\" width=\"1052\">\n<tbody>\n<tr>\n<td>\n<p>\u00a0<strong>EN BREF :<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Cr\u00e9ation\u00a0<\/strong>: Juillet 2018<\/li>\n<li><strong>Lieu<\/strong>\u00a0: Orsay (si\u00e8ge), Lyon Gerland (\u00e9tablissement secondaire)<\/li>\n<li><strong>Co-fondateurs<\/strong>\u00a0:\u00a0<a href=\"https:\/\/www.facebook.com\/watch\/?v=358146368380918\">Docteur Martine CAROFF (CSO)<\/a>, Pr Jean-Marc CAVAILLON (Directeur), Alexey NOVIKOV (Resp. CMC) et Fr\u00e9d\u00e9ric CAROFF (CEO)<\/li>\n<li><strong>Nombre de personnes<\/strong>\u00a0: 7<\/li>\n<li><strong>Financement\u00a0<\/strong>: programme H2020 Instrument PME Phase 1 (contrat 868937) \/ Financement preuve de concept du Canc\u00e9rop\u00f4le CLARA\/ 1<sup>\u00e8re<\/sup>\u00a0lev\u00e9e de fonds 2M\u20ac pr\u00e9vue en 2020, 2<sup>\u00e8me<\/sup>\u00a0lev\u00e9e de fonds entre 6 et 8M\u20ac<\/li>\n<li><strong>Palmar\u00e8s\u00a0:<\/strong>\u00a0FEDER 2018 \/\u00a0<a href=\"http:\/\/www.wilco-startup.com\/wilco-healthcare\/\">WILCO Healthcare 2019<\/a>\u00a0\/ Label French Tech Seed 2019 \/\u00a0<a href=\"https:\/\/ec.europa.eu\/info\/research-and-innovation\/funding\/funding-opportunities\/prizes\/eu-prize-women-innovators\/eu-prize-women-innovators-2019_en\">European Women Innovators Prize 2019<\/a>\u00a0\/ S\u00e9lection pour le concours iLab 2019.<\/li>\n<li><strong>Site internet<\/strong>\u00a0:\u00a0<a href=\"http:\/\/www.hephaistos-pharma.com\/\">http:\/\/www.hephaistos-pharma.com\/<\/a><\/li>\n<li><strong>Contact Chef de projet\u00a0<\/strong>:\u00a0<u>loseph.andr\u00e9[@]pulsalys.fr<\/u><\/li>\n<li><strong>Laboratoire impliqu\u00e9\u00a0:<\/strong>\u00a0Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL\u00a0: INSERM, CNRS, UCBL, CLB, HCL, ISPB)<\/li>\n<li><strong>Chercheurs impliqu\u00e9s\u00a0:<\/strong>\u00a0Pr Charles Dumontet\u00a0\/ Dr Martine CAROFF<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>\u00a0<img loading=\"lazy\" decoding=\"async\" class=\"alignnone \" src=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2019\/06\/VIVATech-2019.png\" width=\"986\" height=\"658\" \/><br \/>\n<\/strong>Dr Martine Caroff (Photo 1 : 3<sup>\u00e8me<\/sup> en partant de la gauche, Photo 2 : <sup>3\u00e8me<\/sup> en partant de la droite) re\u00e7oit son troph\u00e9e <a href=\"https:\/\/ec.europa.eu\/info\/research-and-innovation\/funding\/funding-opportunities\/prizes\/eu-prize-women-innovators\/eu-prize-women-innovators-2019_en\" target=\"_blank\" rel=\"noopener noreferrer\">European Women Innovators Prize 2019<\/a> lors de l&#8217;\u00e9v\u00e9nement VIVA Technology<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A l\u2019interface de l\u2019immunologie et de l\u2019oncologie, la soci\u00e9t\u00e9 de biotechnologie HEPHAISTOS-Pharma cr\u00e9\u00e9e en juillet 2018 allie les expertises du Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL\u00a0: INSERM\/CNRS\/UCBL\/CLB\/HCL\/ISPB) et de la soci\u00e9t\u00e9 parisienne LPS-Biosciences sp\u00e9cialis\u00e9e dans l\u2019infectiologie et les vaccins. La soci\u00e9t\u00e9, laur\u00e9ate du concours d\u2019innovation i-Lab 2019, b\u00e9n\u00e9ficie du programme de co-maturation de [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":15695,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567,568],"tags":[],"class_list":["post-15683","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-successstories-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sylvain DUC\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/\"},\"author\":{\"name\":\"Sylvain DUC\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\"},\"headline\":\"HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer\",\"datePublished\":\"2019-08-02T07:59:39+00:00\",\"dateModified\":\"2019-11-06T08:38:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/\"},\"wordCount\":965,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/08\/Hepha.png\",\"articleSection\":[\"News\",\"Success Stories\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/\",\"url\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/\",\"name\":\"HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/08\/Hepha.png\",\"datePublished\":\"2019-08-02T07:59:39+00:00\",\"dateModified\":\"2019-11-06T08:38:37+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/08\/Hepha.png\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/08\/Hepha.png\",\"width\":1297,\"height\":723},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\",\"name\":\"Sylvain DUC\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/sylvain\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/","twitter_misc":{"Written by":"Sylvain DUC","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/"},"author":{"name":"Sylvain DUC","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca"},"headline":"HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer","datePublished":"2019-08-02T07:59:39+00:00","dateModified":"2019-11-06T08:38:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/"},"wordCount":965,"image":{"@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/08\/Hepha.png","articleSection":["News","Success Stories"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/","url":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/","name":"HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/08\/Hepha.png","datePublished":"2019-08-02T07:59:39+00:00","dateModified":"2019-11-06T08:38:37+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/08\/Hepha.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/08\/Hepha.png","width":1297,"height":723},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/hephaistos-pharma-soutenue-par-pulsalys-booste-limmunotherapie-contre-le-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"HEPHAISTOS PHARMA, incub\u00e9e \u00e0 PULSALYS, booste l\u2019immunoth\u00e9rapie contre le cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca","name":"Sylvain DUC","url":"https:\/\/www.satt.fr\/en\/author\/sylvain\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/15683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=15683"}],"version-history":[{"count":2,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/15683\/revisions"}],"predecessor-version":[{"id":16774,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/15683\/revisions\/16774"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/15695"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=15683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=15683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=15683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}